Nutcracker Therapeutics
- Founded: 2018
- Location: Emeryville, CA
- Employee range: 50 - 200
- Clinical stage: Clin0
- Therapy area: HPV-driven tumors
- Drug types: ONC
- Lead product: NTX-250
- Product link: https://www.nutcrackerx.com/pipeline/
- Funding: $167M C Mar 2022; $60M B Sep 2020
nutcrackerx.com linkedin.com job board
Short description:
mRNA manufacturing device
Drug notes:
NTX-0565 RD T cell lymphoma; NTX-0470 RD genitourinary tumors
Long description:
Nutcracker Therapeutics is developing and producing RNA therapeutics as fast as possible using microfluidic technology. RNA therapeutics have many advantages - versatility, speed, efficacy and safety. However, manufacturing has hindered the production of RNA therapeutics for multiple diseases. Through the use of their proprietary Biochip-based manufacturing platform, Nutcracker is using biochemistry, nanoparticle delivery and microfluidic engineering to automate and scale RNA therapeutics. As Nutcracker is focused on the technology, they are partnering with experts in different diseases to bring their products to patients. Currently, Nutcracker has 3 programs close to clinical trials for different cancers.
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com